Download PDF
Exp Clin Endocrinol Diabetes 2003; 111(2): 91-96
DOI: 10.1055/s-2003-39236
Article

J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York

Pioglitazone Increases Serum Magnesium Levels in Glucose-Intolerant Subjects. A Randomized, Controlled Trial

F. Guerrero-Romero 1 , M. Rodríguez-Morán 1
  • 1Medical Research Unit in Clinical Epidemiology of the Mexican Social Security Institute (FGR, MRM), and the Research Group on Diabetes and Chronic Illnesses (FGR, MRM), Durango, Mexico
Further Information

Publication History

Received: January 4, 2002 First decision: April 11, 2002

Accepted: October 8, 2002

Publication Date:
14 May 2003 (online)

Also available at
    Permissions and Reprints

Abstract

Although thiazolidinediones and magnesium supplementation improves insulin action and increases HDL-cholesterol, the potential link between serum magnesium and thiazolidinediones has received little attention. Focusing on the increase of serum magnesium, 63 eligible subjects were enrolled and randomly allocated to receive either 30 mg Pioglitazone once daily (Group A) or lifestyle intervention (Group B) during 12 weeks. Subjects were eligible if they were glucose-intolerant, and excluded if they had high blood pressure, diabetes or abnormal liver function tests. The personnel assessing outcomes were blinded to group assignment. Of the 63 eligible subjects, 3 dropped out (one in group A, and two in Group B) because they moved out of the city. So, 30 subjects in each group, who satisfactorily completed the follow-up, were included in the analysis of data. There were no serious adverse events or side effects due to Pioglitazone or lifestyle intervention. At baseline, the groups did not differ significantly in serum magnesium levels 1.73 ± 0.17 versus 1.72 ± 0.14 mg/dl, p = 0.80. Subjects who received Pioglitazone significantly increased their serum magnesium to 1.93 ± 0.16 mg/dl whereas in the lifestyle intervention group the increase was 1.74 ± 0.25 mg/dl, p < 0.0001. What this study showed was a significant increase in the serum magnesium levels of glucose-intolerant subjects who received 30 mg Pioglitazone once daily.

Key words

Pioglitazone - Magnesium - Thiazolidinediones - Impaired glucose tolerance

References

  • 1 Belcher G, Matthews D R. Safety and tolerability of Pioglitazone.  Exp Clin Endocrinol Diabetes. 2000;  108 (Suppl 2) S267-S273
    PubMedGoogle Scholar
  • 2 Buse J B. Pioglitazone in the treatment of type 2 diabetes mellitus: U. S. clinical experience.  Exp Clin Endocrinol Diabetes. 2000;  108 (Suppl 2) S250-S255
    PubMedGoogle Scholar
  • 3 Corica F, Allegra A, Di Benedetto A, Giacobbe M S, Romano G, Cucinotta D, Buemi M, Ceruso D. Effects of oral magnesium supplementation on plasma lipid concentrations in patients with non-insulin-dependent diabetes mellitus.  Magnes Res. 1994;  7 43-47
    PubMedGoogle Scholar
  • 4 Eckland D A, Danhof M. Clinical pharmacokinetics of Pioglitazone.  Exp Clin Endocrinol Diabetes. 2000;  108 (Suppl 2) S234-S242
    PubMedGoogle Scholar
  • 5 Eibl N L, Kopp H P, Nowak H R, Schnack C J, Hopmeier P G, Schernthaner G. Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy.  Diabetes Care. 1995;  18 188-192
    PubMedGoogle Scholar
  • 6 Ellenberg S, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2. Practical issues and specific cases.  Ann Intern Med. 2000;  133 464-470
    PubMedGoogle Scholar
  • 7 Eriksson J, Lindström J, Valle T, Aunola S, Hämaäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljnanen T, Uusitupa M, Tuomilehto J. Finnish Diabetes Prevention Group: Prevention of type II diabetes in subjects with impaired glucose tolerance: The diabetes prevention study (DPS) in Finland.  Diabetologia. 1999;  42 793-801
    CrossrefPubMedGoogle Scholar
  • 8 Eriksson K F, Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö preventive trial with diet and exercise.  Diabetologia. 1998;  41 1010-1016
    CrossrefPubMedGoogle Scholar
  • 9 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.  Diabetes Care. 1999;  22 (Suppl. 1) S5-S19
    PubMedGoogle Scholar
  • 10 Fonseca V A, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized, controlled trial.  JAMA. 2000;  283 1695-1702
    CrossrefPubMedGoogle Scholar
  • 11 Fürchtenbush M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones, and glinides in the treatment of type 2 diabetes mellitus.  Exp Clin Endocrinol Diabetes. 2000;  108 160-163
    PubMedGoogle Scholar
  • 12 Guerrero-Romero F, Rodriguez-Moran M. Hypomagnesemia is linked to low serum HDL-cholesterol irrespective of serum glucose levels.  J Diabetes Complications. 2000;  14 272-276
    CrossrefPubMedGoogle Scholar
  • 13 Hanefeld M, Göke B. Combining Pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes.  Exp Clin Endocrinol Diabetes. 2000;  108 (Suppl 2) 256-266
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Hu F B, Manson JoAnn E, Stamfer M J, Colditz G, Liu S, Solomon C G, Willet W. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.  N Engl J Med. 2001;  345 790-797
    CrossrefPubMedGoogle Scholar
  • 15 Humphries S, Kushner H, Falkner B. Low dietary magnesium is associated with insulin resistance in a sample of young, nondiabetic black Americans.  Am J Hypertens. 1999;  12 747-756
    CrossrefPubMedGoogle Scholar
  • 16 Itoh K, Kawasaka T, Nakamura M. The effects of high oral magnesium supplementation on blood pressure, serum lipids and related variables in apparently healthy Japanese subjects.  Br J Nutr. 1997;  78 737-750
    CrossrefPubMedGoogle Scholar
  • 17 Jones B, Jarvis P, Lewis J A, Ebbut A F. Trials to assess equivalence: the importance of rigorous methods.  BMJ. 1996;  313 36-39
    CrossrefPubMedGoogle Scholar
  • 18 Kao W HL, Folsom A R, Nieto J F, Mo J-P, Watson R L, Brancati F L. Serum and dietary magnesium and the risk for type 2 diabetes mellitus.  Arch Intern Med. 1999;  159 2151-2159
    CrossrefPubMedGoogle Scholar
  • 19 Kemnitz J W, Elson D F, Roecker E B, Baum S T, Bergman R N, Meglasson M D. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin resistant rhesus monkeys.  Diabetes. 1994;  43 204-211
    PubMedGoogle Scholar
  • 20 King H, Aubert R E, Herman W H. Global burden of diabetes, 1995 - 2025: Prevalence, numerical estimates, and projections.  Diabetes Care. 1998;  21 1414-1431
    CrossrefPubMedGoogle Scholar
  • 21 Komers R, Vrána A. Thiazolidinediones - tools for the research of metabolic syndrome X.  Physiol Res. 1998;  47 212-225
    PubMedGoogle Scholar
  • 22 Lefèbvre P J, Scheen A J. Improving the action of insulin.  Clin Invest Med. 1995;  18 340-347
    PubMedGoogle Scholar
  • 23 Makuch R, Johnson M. Issues in planning and interpreting active control equivalences studies.  J Clin Epidemiol. 1989;  42 503-511
    CrossrefPubMedGoogle Scholar
  • 24 Malpuech-Brugère C, Nowacki W, Rock E, Gueux E, Mazur A, Rayssiguier Y. Enhanced tumor necrosis factor-alpha production following endotoxin challenge in rats: an early event during magnesium deficiency.  Biochem Biophys Acta. 1999;  1453 35-40
    PubMedGoogle Scholar
  • 25 Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: Insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 26 Mejía-Aranguré J M, Fajardo-Gutierrez A, Gómez-delgado A, Cuevas-Uriostegui M L, Hernández Hernández D M, Garduño-Espinoza J, Navarrete-Navarro S, Veláquez-Pérez L, Martínez-García M C. El tamaño de la muestra. Un enfoque práctico en la investigación clínica pediátrica.  Bol Med Hosp Infant Mex. 1995;  52 381-391
    PubMedGoogle Scholar
  • 27 Nadler J, Scott S. Evidence that Pioglitazone increases intracellular free magnesium concentration in freshly isolated rat adypocites.  Biochem Biophys Res Commun. 1994;  202 416-421
    CrossrefPubMedGoogle Scholar
  • 28 Nadler J L, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis.  Hypertension. 1993;  21 1024-1029
    PubMedGoogle Scholar
  • 29 Paolisso G, Barbagallo M. Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium.  Am J Hypertens. 1997;  10 346-355
    CrossrefPubMedGoogle Scholar
  • 30 Paolisso G, Scheen A, D'Onofrio F, Lefèbvre P. Magnesium and glucose homeostasis.  Diabetologia. 1990;  33 511-514
    CrossrefPubMedGoogle Scholar
  • 31 Pfohl M, Schatz H. Strategies for the prevention of type 2 diabetes.  Exp Clin Endocrinol Diabetes. 2001;  109 (Suppl 2) S240-S249
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Reaven G M. Insulin resistance, how important is it to treat?.  Exp Clin Endocrinol Diabetes. 2000;  108 (Suppl 2) S271-S280
    PubMedGoogle Scholar
  • 33 Reaven G M. Pathophysiology of insulin resistance in human disease.  Physiol Rev. 1995;  75 473-486
    PubMedGoogle Scholar
  • 34 Resnick L M. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of “syndrome X”.  Am J Hypertens. 1993;  6 123S-134S
    PubMedGoogle Scholar
  • 35 Reynolds T. The ethics of placebo-controlled trials.  Ann Intern Med. 2000;  133 491-492
    PubMedGoogle Scholar
  • 36 Ricen E, Servis K L, DeRusso P, Kershaw A, Stephen T, Rude R K. Determination of intracellular free magnesium by nuclear magnetic resonance in human magnesium deficiency.  J Am Coll Nutr. 1989;  8 580-587
    PubMedGoogle Scholar
  • 37 Rosolova H, Mayer Jr O, Reaven G. Effect of variations in plasma magnesium concentration on resistance to insulin-mediated glucose disposal in nondiabetic subjects.  J Clin Endocrinol Metab. 1997;  82 3783-3785
    CrossrefPubMedGoogle Scholar
  • 38 Schneider R, Lessem J, Lekich H. Pioglitazone is effective in the treatment of patients with type 2 diabetes. Pioglitazone 001 Study Group.  Diabetes. 1999;  48 (Suppl 1) A109
    PubMedGoogle Scholar
  • 39 Schulz K, Chalmers I, Altman D. The landscape and lexicon of blinding in randomized trials.  Ann Intern Med. 2002;  136 254-259
    PubMedGoogle Scholar
  • 40 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high Blood Pressure . Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high Blood Pressure.  Arch Intern Med. 1997;  157 2413-2446
    CrossrefPubMedGoogle Scholar
  • 41 Tan M H. How Pioglitazone affects glucose and lipid metabolism.  Exp Clin Endocrinol Diabetes. 2000;  108 (Suppl 2) S223-S224
    PubMedGoogle Scholar
  • 42 Temple R, Ellenberg S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1. Ethical and scientific issues.  Ann Intern Med. 2000;  133 455-463
    PubMedGoogle Scholar
  • 43 Tosiello L. Hypomagnesemia and diabetes mellitus. A review of clinical implications.  Arch Intern Med. 1996;  156 1143-1146
    CrossrefPubMedGoogle Scholar
  • 44 Vanroelen W F, Van Gaal L F, Van Rooy P E, De Leeuw I H. Serum and erythrocyte magnesium levels in type I and type II diabetics.  Acta Diabetol Lat. 1985;  22 185-190
    PubMedGoogle Scholar

Fernando Guerrero-Romero

Siqueiros 225 esq./Castañeda

34000 Durango, Dgo.

Mexico

Phone: + 526188120997

Fax: + 52 61 88 13 20 14

Email: guerrero_romero@hotmail.com

Email: guerrero_romero@members.nyas.org

      >